JPWO2019173602A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019173602A5
JPWO2019173602A5 JP2020546962A JP2020546962A JPWO2019173602A5 JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5 JP 2020546962 A JP2020546962 A JP 2020546962A JP 2020546962 A JP2020546962 A JP 2020546962A JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5
Authority
JP
Japan
Prior art keywords
optionally substituted
virus
alkyl
different
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546962A
Other languages
English (en)
Japanese (ja)
Other versions
JP7371931B2 (ja
JP2021517132A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021168 external-priority patent/WO2019173602A1/fr
Publication of JP2021517132A publication Critical patent/JP2021517132A/ja
Publication of JPWO2019173602A5 publication Critical patent/JPWO2019173602A5/ja
Priority to JP2023176993A priority Critical patent/JP2024009953A/ja
Application granted granted Critical
Publication of JP7371931B2 publication Critical patent/JP7371931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546962A 2018-03-07 2019-03-07 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 Active JP7371931B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023176993A JP2024009953A (ja) 2018-03-07 2023-10-12 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639725P 2018-03-07 2018-03-07
US62/639,725 2018-03-07
PCT/US2019/021168 WO2019173602A1 (fr) 2018-03-07 2019-03-07 Compositions thérapeutiques à base de nucléosides et de nucléotides contenant 4-halogène et utilisations associées

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023176993A Division JP2024009953A (ja) 2018-03-07 2023-10-12 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Publications (3)

Publication Number Publication Date
JP2021517132A JP2021517132A (ja) 2021-07-15
JPWO2019173602A5 true JPWO2019173602A5 (fr) 2022-03-14
JP7371931B2 JP7371931B2 (ja) 2023-10-31

Family

ID=67846796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546962A Active JP7371931B2 (ja) 2018-03-07 2019-03-07 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2023176993A Pending JP2024009953A (ja) 2018-03-07 2023-10-12 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023176993A Pending JP2024009953A (ja) 2018-03-07 2023-10-12 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Country Status (14)

Country Link
US (2) US20210308168A1 (fr)
EP (1) EP3762372A4 (fr)
JP (2) JP7371931B2 (fr)
KR (1) KR20200140274A (fr)
CN (1) CN112074506A (fr)
AU (1) AU2019231725B2 (fr)
BR (1) BR112020018209A2 (fr)
CA (1) CA3093222A1 (fr)
EA (1) EA202092117A1 (fr)
GB (2) GB2611644B (fr)
IL (1) IL277160B1 (fr)
PH (1) PH12020551404A1 (fr)
SG (1) SG11202008527WA (fr)
WO (1) WO2019173602A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2020418425A1 (en) * 2019-10-08 2022-04-14 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20230167166A1 (en) * 2020-04-24 2023-06-01 Memorial Sloan Kettering Cancer Center Targeted therapy for the treatment & prevention of life-threatening complications of infection
US20240025938A1 (en) * 2020-08-27 2024-01-25 Emory University Novel forms of antiviral nucleosides
AU2021401398A1 (en) * 2020-12-18 2023-06-29 Merck Sharp & Dohme Llc Synthesis of antiviral nucleosides
CN114644666A (zh) * 2020-12-18 2022-06-21 上海特化医药科技有限公司 5’-核苷前药的制备方法及中间体
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112778387A (zh) * 2021-01-15 2021-05-11 杭州科巢生物科技有限公司 一种Molnupiravir晶型A及其制备方法
WO2022174179A1 (fr) * 2021-02-15 2022-08-18 Emory University Compositions thérapeutiques à base de nucléosides et de nucléotides contenant du 4'-halogène et utilisations associées
WO2022174194A1 (fr) * 2021-02-15 2022-08-18 Emory University Compositions thérapeutiques à base de nucléosides et de nucléotides contenant du 4'-halogène et utilisations associées
WO2022218274A1 (fr) * 2021-04-15 2022-10-20 中国科学院上海药物研究所 Analogue de nucléoside et son utilisation
US11407779B1 (en) 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
CN112979733B (zh) * 2021-04-25 2021-09-10 南京颐媛生物医学研究院有限公司 抗乙肝病毒的化合物及其制备方法和应用
CN113278040B (zh) * 2021-06-16 2022-07-05 苏州立新制药有限公司 5’-异丁酰基-n4-羟基胞苷的制备方法
WO2022262845A1 (fr) * 2021-06-18 2022-12-22 Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. Dérivés d'ester de n4-hydroxycytidine et leur utilisation
WO2023012329A1 (fr) 2021-08-06 2023-02-09 Intervet International B.V. Méthode de traitement de maladies virales vétérinaires
CA3230382A1 (fr) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Molecules d'acide nucleique interferent court modifiees (sina) et leurs utilisations
CN113880902A (zh) * 2021-10-26 2022-01-04 江苏睿实生物科技有限公司 一种Molnupiravir药物中间体及其制备方法
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN114478658A (zh) * 2022-02-22 2022-05-13 苏州正济药业有限公司 一种莫那比拉韦的合成方法
CN116947947A (zh) * 2022-04-20 2023-10-27 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
CN117567310A (zh) * 2023-11-28 2024-02-20 重庆智合生物医药有限公司 一种神经酰胺np1的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
JPWO2004024185A1 (ja) * 2002-09-11 2006-01-26 道男 石橋 医薬または化粧料
EP2068912A2 (fr) * 2006-09-27 2009-06-17 Coley Pharmaceutical Group, Inc. Compositions de ligands tlr et d'antiviraux
WO2009058800A2 (fr) * 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthèse de nucléosides
US8962580B2 (en) * 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
ES2636448T3 (es) 2011-12-20 2017-10-05 Riboscience Llc Derivados de nucleósido 2',4'-difluoro-2'-metil sustituidos como inhibidores de la replicación del ARN del VHC
AP3913A (en) * 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
US9187515B2 (en) * 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014186637A1 (fr) * 2013-05-16 2014-11-20 Riboscience Llc Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués
EP3013340B9 (fr) * 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Nucléosides, nucléotides substitués et leurs analogues
WO2015051169A2 (fr) * 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Molécules de polynucléotides et leurs utilisations
SG10201804835VA (en) * 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2015280234B2 (en) * 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2016134054A1 (fr) * 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
WO2016134056A1 (fr) 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
BR112018002399A2 (pt) * 2015-08-06 2018-09-25 Chimerix, Inc. nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais
WO2017040892A1 (fr) 2015-09-02 2017-03-09 Abbvie Inc. Composés anti-viraux
WO2017040895A1 (fr) 2015-09-02 2017-03-09 Abbvie Inc. Composés anti-viraux
WO2017040896A1 (fr) * 2015-09-02 2017-03-09 Abbvie Inc. Composés anti-viraux
US11963972B2 (en) * 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
US20200179428A1 (en) * 2016-06-20 2020-06-11 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

Similar Documents

Publication Publication Date Title
JPWO2019173602A5 (fr)
JP5108750B2 (ja) Hdac阻害剤の医薬製剤
US20110015273A1 (en) Stable pharmaceutical aqueous compositions
GB2589205A (en) 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto
ES2432666T3 (es) Suspensión pediátrica estabilizada de carisbamato
JP2008522981A5 (fr)
JP2010528051A (ja) デング感染症の治療または予防のための抗ウイルス薬
DE4218572A1 (de) Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
BRPI0506705A (pt) composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos
CH684054A5 (de) Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten.
EA034559B1 (ru) Жидкая фармацевтическая композиция, содержащая пеметрексед
WO2001076570A2 (fr) Utilisation de substances agissant en tant qu'inhibiteurs de la cascade de signaux raf/mek/erk pour produire un medicament contre les virus a adn et a arn
BR112012029212A2 (pt) formulação de paracetamol injetável pronta para o uso estável
ES2318277T3 (es) Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico.
ES2272383T3 (es) Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison.
KR102605030B1 (ko) 카바메이트 화합물을 포함하는 비경구용 액상 제제
TW200812592A (en) Use of strobilurins for the treatment of disorders of iron metabolism
US20190328663A1 (en) Liposomes for the treatment of viral infections
JP6786504B2 (ja) ウマにおける発熱の処置及び防止のための組成物及び方法
ES2388253B1 (es) Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia
US20060229356A1 (en) Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions
EA202090172A1 (ru) Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью
TWI316403B (en) Glycyrrhizin containing pharmaceutical composition
US20090143313A1 (en) Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds
BR112020012521A2 (pt) agente terapêutico para glaucoma compreendendo agonista de fp e beta-bloqueador